{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:00:20Z","timestamp":1793833220359,"version":"4.6.1"},"reference-count":84,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1016\/j.bone.2008.01.027","type":"journal-article","created":{"date-parts":[[2008,4,15]],"date-time":"2008-04-15T08:59:28Z","timestamp":1208249968000},"page":"1007-1013","source":"Crossref","is-referenced-by-count":152,"title":["The pathogenesis of the bone disease of multiple myeloma"],"prefix":"10.1016","volume":"42","author":[{"given":"Claire M.","family":"Edwards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory R.","family":"Mundy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2008.01.027_bib1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0959-8049(97)10133-2","article-title":"Myeloma bone disease","volume":"34","author":"Mundy","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bone.2008.01.027_bib2","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1056\/NEJM197411142912001","article-title":"Evidence for the secretion of an osteoclast stimulating factor in myeloma","volume":"291","author":"Mundy","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2008.01.027_bib3","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2141.1982.tb03936.x","article-title":"Quantitative histology of myeloma-induced bone changes","volume":"52","author":"Valentin","year":"1982","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bone.2008.01.027_bib4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1600-0609.1992.tb00046.x","article-title":"Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption","volume":"49","author":"Taube","year":"1992","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bone.2008.01.027_bib5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI115305","article-title":"Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma","volume":"88","author":"Bataille","year":"1991","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2008.01.027_bib6","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1302\/0301-620X.71B2.2925748","article-title":"Does myeloma secrete an osteoblast inhibiting factor?","volume":"71","author":"Evans","year":"1989","journal-title":"J Bone Joint Surg Br"},{"key":"10.1016\/j.bone.2008.01.027_bib7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/1097-0142(19900701)66:1<167::AID-CNCR2820660130>3.0.CO;2-9","article-title":"Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications","volume":"66","author":"Bataille","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2008.01.027_bib8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1600-0609.1998.tb01073.x","article-title":"Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma","volume":"61","author":"Abildgaard","year":"1998","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bone.2008.01.027_bib9","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/clinchem\/47.4.686","article-title":"Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis","volume":"47","author":"Woitge","year":"2001","journal-title":"Clin Chem"},{"key":"10.1016\/j.bone.2008.01.027_bib10","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1056\/NEJM198708273170902","article-title":"Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells","volume":"317","author":"Garrett","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2008.01.027_bib11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/332083a0","article-title":"Autocrine generation and requirement of BSF-2\/IL-6 for human multiple myelomas","volume":"332","author":"Kawano","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.bone.2008.01.027_bib12","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","article-title":"IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells","volume":"103","author":"Lee","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib13","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood.V74.4.1266.1266","article-title":"Production of cytokines by bone marrow cells obtained from patients with multiple myeloma","volume":"74","author":"Lichtenstein","year":"1989","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/36593","article-title":"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function","volume":"390","author":"Anderson","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.bone.2008.01.027_bib15","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bone.2008.01.027_bib16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.bone.2008.01.027_bib17","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.bone.2008.01.027_bib18","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1073\/pnas.97.4.1566","article-title":"RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism","volume":"97","author":"Li","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bone.2008.01.027_bib19","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1006\/bbrc.1998.8697","article-title":"Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor\/osteoprotegerin","volume":"247","author":"Mizuno","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bone.2008.01.027_bib20","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"PNAS"},{"key":"10.1016\/j.bone.2008.01.027_bib21","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1309\/BPET-F2PE-P2BD-J3P3","article-title":"RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone","volume":"117","author":"Roux","year":"2002","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.bone.2008.01.027_bib23","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood.V98.7.2269","article-title":"Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease","volume":"98","author":"Seidel","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib24","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2004.05092.x","article-title":"Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)","volume":"126","author":"Politou","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bone.2008.01.027_bib25","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand\u2013osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib26","first-page":"5438","article-title":"Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo","volume":"63","author":"Farrugia","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2008.01.027_bib27","first-page":"360a","article-title":"Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL","volume":"96","author":"Shipman","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib28","first-page":"912","article-title":"Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand\/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells","volume":"63","author":"Shipman","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2008.01.027_bib29","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","article-title":"Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma","volume":"98","author":"Croucher","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib30","first-page":"287","article-title":"Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma","volume":"63","author":"Vanderkerken","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2008.01.027_bib31","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/cncr.11133","article-title":"Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma","volume":"97","author":"Oyajobi","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2008.01.027_bib32","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","article-title":"Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity","volume":"116","author":"Yaccoby","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bone.2008.01.027_bib33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1365-2141.2003.04561.x","article-title":"Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma","volume":"123","author":"Terpos","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bone.2008.01.027_bib34","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood.V96.2.671","article-title":"Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma","volume":"96","author":"Choi","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib35","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.exphem.2004.11.015","article-title":"MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells","volume":"33","author":"Oba","year":"2005","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bone.2008.01.027_bib36","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","article-title":"Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease","volume":"102","author":"Oyajobi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib37","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1172\/JCI200113116","article-title":"Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease","volume":"108","author":"Choi","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2008.01.027_bib38","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.1994.tb08304.x","article-title":"Bone marrow angiogenesis and progression in multiple myeloma","volume":"87","author":"Vacca","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bone.2008.01.027_bib39","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1084\/jem.190.2.293","article-title":"Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption","volume":"190","author":"Niida","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.bone.2008.01.027_bib40","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/1078-0432.CCR-06-2258","article-title":"Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin","volume":"13","author":"Tanaka","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bone.2008.01.027_bib41","first-page":"299","article-title":"SDF-1 and CXCR4 in normal and malignant hematopoiesis","volume":"19","author":"Juarez","year":"2004","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.bone.2008.01.027_bib42","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1359\/jbmr.2003.18.8.1404","article-title":"Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration","volume":"18","author":"Yu","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2008.01.027_bib43","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1158\/0008-5472.CAN-04-1844","article-title":"CXCR4 regulates growth of both primary and metastatic breast cancer","volume":"64","author":"Smith","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2008.01.027_bib44","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","article-title":"Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma","volume":"109","author":"Alsayed","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib45","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-04-1687","article-title":"Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients","volume":"65","author":"Zannettino","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2008.01.027_bib46","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood.V96.5.1953","article-title":"Cell\u2013cell contact between marrow stromal cells and myeloma cells via VCAM-1 and a4b1-integrin enhances production of osteoclast-stimulating activity","volume":"96","author":"Michigami","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib47","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1182\/blood-2004-01-0236","article-title":"Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis","volume":"104","author":"Mori","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib48","first-page":"S180","article-title":"Expression of RANK ligand (RANKL) by myeloma cells requires binding to bone marrow stromal cells via an a4b1\u2013VCAM-1 interaction","volume":"23","author":"Oyayobi","year":"1998","journal-title":"Bone"},{"key":"10.1016\/j.bone.2008.01.027_bib49","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1158\/0008-5472.CAN-03-1131","article-title":"Cancer and the microenvironment: myeloma\u2013osteoclast interactions as a model","volume":"64","author":"Yaccoby","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2008.01.027_bib50","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","article-title":"Osteoclasts enhance myeloma cell growth and survival via cell\u2013cell contact: a vicious cycle between bone destruction and myeloma expansion","volume":"104","author":"Abe","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib51","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0092-8674(01)00571-2","article-title":"LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development","volume":"107","author":"Gong","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.bone.2008.01.027_bib52","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa013444","article-title":"High bone density due to a mutation in LDL-receptor-related protein 5","volume":"346","author":"Boyden","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2008.01.027_bib53","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1083\/jcb.200201089","article-title":"Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistant embryonic eye vascularization in mice deficient in LRP5, a Wnt coreceptor","volume":"157","author":"Kato","year":"2002","journal-title":"J Cell Biol"},{"key":"10.1016\/j.bone.2008.01.027_bib54","doi-asserted-by":"crossref","first-page":"17406","DOI":"10.1073\/pnas.0505259102","article-title":"Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice","volume":"102","author":"Clement-Lacroix","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bone.2008.01.027_bib55","first-page":"S82","article-title":"Lithium inhibits the development of myeloma bone disease in vivo","volume":"21","author":"Edwards","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2008.01.027_bib56","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2008.01.027_bib57","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1359\/jbmr.2003.18.10.1842","article-title":"BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop","volume":"18","author":"Rawadi","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2008.01.027_bib58","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bone.2006.03.017","article-title":"Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia","volume":"39","author":"Li","year":"2006","journal-title":"Bone"},{"key":"10.1016\/j.bone.2008.01.027_bib59","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1359\/jbmr.060311","article-title":"Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass","volume":"21","author":"Morvan","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2008.01.027_bib60","first-page":"1011","article-title":"Role of Dickkopf 1(Dkk) in myeloma bone disease and modulation by the proteasome inhibitor velcade","volume":"19","author":"Oyajobi","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2008.01.027_bib61","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1634\/stemcells.2005-0220","article-title":"A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma","volume":"24","author":"Gunn","year":"2006","journal-title":"Stem Cells"},{"key":"10.1016\/j.bone.2008.01.027_bib62","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","article-title":"Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo","volume":"109","author":"Yaccoby","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib63","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2004-12-4940","article-title":"Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2","volume":"106","author":"Oshima","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib64","first-page":"1101","article-title":"Enhancement of osteoblast differentiation by inhibition of TGF-beta signaling suppresses myeloma cell growth and protects from destructive bone lesions","volume":"21","author":"Takeuchi","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2008.01.027_bib65","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib66","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1182\/blood-2005-03-1080","article-title":"IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma","volume":"106","author":"Ehrlich","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib67","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1182\/blood.V91.3.806","article-title":"Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma","volume":"91","author":"Seidel","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib68","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2141.2004.05299.x","article-title":"Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival","volume":"128","author":"Andersen","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bone.2008.01.027_bib69","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2006-07-034884","article-title":"HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma","volume":"109","author":"Standal","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib70","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1182\/blood-2005-02-0691","article-title":"Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma","volume":"106","author":"Richardson","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib71","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3816\/CLM.2003.n.022","article-title":"A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma","volume":"4","author":"Yang","year":"2003","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.bone.2008.01.027_bib72","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.20888","article-title":"Bortezomib in recurrent and\/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function","volume":"103","author":"Jagannath","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2008.01.027_bib73","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2141.2005.05540.x","article-title":"Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma","volume":"129","author":"Jagannath","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bone.2008.01.027_bib74","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2008.01.027_bib75","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1172\/JCI16198","article-title":"Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro","volume":"111","author":"Garrett","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2008.01.027_bib76","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.bbrc.2005.05.098","article-title":"Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function","volume":"333","author":"Zavrski","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bone.2008.01.027_bib77","doi-asserted-by":"crossref","first-page":"154a","DOI":"10.1182\/blood.V108.11.509.509","article-title":"PTH and bortezomib suppresses growth of primary human myeloma through increased bone formation in vivo","volume":"108","author":"Pennisi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib78","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2141.2005.05733.x","article-title":"Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma","volume":"131","author":"Zangari","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bone.2008.01.027_bib79","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/sj.leu.2403758","article-title":"High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation","volume":"19","author":"Shimazaki","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bone.2008.01.027_bib80","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3816\/CLM.2006.n.047","article-title":"Response to bortezomib and activation of osteoblasts in multiple myeloma","volume":"7","author":"Zangari","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.bone.2008.01.027_bib81","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood.V108.11.508.508","article-title":"The proteasome inhibitor bortezomib affects osteoblastogenesis and bone formation in vitro and in vivo in multiple myeloma patients","volume":"108","author":"Giuliani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bone.2008.01.027_bib82","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2141.2006.06356.x","article-title":"Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma","volume":"135","author":"Terpos","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bone.2008.01.027_bib83","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cncr.11138","article-title":"A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases","volume":"97","author":"Body","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2008.01.027_bib84","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328208000719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328208000719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T05:28:03Z","timestamp":1588570083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328208000719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["S8756328208000719"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2008.01.027","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}